ArticleClinical and experimental immunology1989
Increased serum levels of IgA1-IgG immune complexes and anti-F(ab')2 antibodies in patients with primary IgA nephropathy.
Article in Clinical and experimental immunology, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 53 citations in OpenAlex.
- Identification and characterization of circulating immune complexes in IgA nephropathy.Science advances · 2022Article
- Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.Journal of clinical medicine · 2021Review
- The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.Frontiers in immunology · 2016Review
- Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.PloS one · 2014Article
- Biomarkers in IgA nephropathy: relationship to pathogenetic hits.Expert opinion on medical diagnostics · 2013Review
- Article
- Genetics and immunopathogenesis of IgA nephropathy.Clinical reviews in allergy & immunology · 2011Review
- Galactosylation of serum IgA1 O-glycans in celiac disease.Journal of clinical immunology · 2011Article
- Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.The Journal of clinical investigation · 2009Article
- IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy.Seminars in nephrology · 2008Review
- Hypercomplementemia in adult patients with IgA nephropathy.Journal of clinical laboratory analysis · 2007Article
- Abnormal glycosylation of serum IgG in patients with IgA nephropathy.Clinical and experimental nephrology · 2006Article
- Experimental IgA nephropathy: factors influencing IgA-immune complex deposition in the glomerulus.Springer seminars in immunopathology · 1994Review
- Pathogenesis of idiopathic IgA nephropathy.Pediatric nephrology (Berlin, Germany) · 1993Review
- Abnormalities of the IgA immune system in members of unrelated pedigrees from patients with IgA nephropathy.Clinical and experimental immunology · 1993Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A solid-phase ELISA was used to detect IgA1 immune complexes (IgA1 ICs) containing IgG and IgM in 38 serum samples from 30 patients with primary IgA nephropathy (IgAN) and 14 subjects with non-IgA chronic glomerulonephritis. A jackfruit lectin, jacalin, was used as the substrate for the selective binding of human IgA1 ICs in serum PEG precipitate (7%). The presence of IgG, A and M antibodies against the F(ab')2 region of IgG was also investigated by the solid-phase ELISA. Six patients were studied during remission and relapse (fever, upper respiratory tract infection and macroheamaturia). The results showed significant increases in serum levels of IgA1 ICs (P less than 0.001) in 39.4% of the IgAN patients, IgA1-IgG ICs (P less than 0.001) in 68.4%, and IgA1-IgM ICs (P less than 0.002) in 10.5% of the patients. A significant increase in IgA1-IgG ICs was observed during relapse (P less than 0.02). Significantly high values of IgG (P less than 0.003) and IgA (P less than 0.001) antibodies directed at the F(ab')2 region of IgG were found. A significant increase in anti F(ab')2 antibodies (class IgA and IgM) was seen in the acute phase of the disease. The data suggest that an increased production of IgA1 ICs occurs in IgAN patients; ICs are mainly IgA1-IgG ICs during relapse. The presence of high serum levels of IgG and IgA antibodies against the F(ab')2 region of IgG indicates that in addition to the multiple anomalies of IgA regulation described in IgAN patients there may be further aberrances.
Indexed as
Identifiers
2788538PMC1541932W2409104883What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.